The design of Medigen Vaccine Biologics Co.(MVC)’s vaccine plant combines both operational flexibility and safety. MVC’s plant is well designed as it is capable of manufacturing vaccines and biologics at the same time, and this vaccine plant conforms to the requirements of BSL 2+ standard. The exterior construction of vaccine plant is completed, and the interior installation is ongoing. PIC/s GMP-certification of MVC’s plant and pilot production are expected to begin next year.
Related news (in Chinese):
1. Chinatimes
2. Global Bio & Investment Monthly 2015 Aug, Cover Story page 64-65.